...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: let’s say Zen has been working towards

a NAZ or TSX listing - what's the time frame we would be looking at to achieve this?

Share
New Message
Please login to post a reply